Monday, September 03, 2012 1:07:48 PM
I imagine a deal would be structured similar to PCYC...they only had drugs in phase II and landed $150 million up front with up to $900 million possible.
http://seekingalpha.com/article/313249-pharmacyclics-scores-big-with-janssen-biotech-deal
PPHM doesn't really need $300 million "up front".
The way PCYC structured it, they received milestone payments after the fifth patient was enrolled in each phase III trial. One was triggered last month: http://www.marketwatch.com/story/pharmacyclics-gets-50-million-milestone-payment-2012-08-20
So, $100-$200 million up front with similar milestones would make a lot of sense to me in partnering bavi. I think the partnership will already be priced in by the time of the announcement and expect we'll be around $1 billion market cap.
PCYC has negative earnings, just entered phase III and has a 4.5 billion market cap. IMO, if bavi works the potential dwarfs that of PCYC's lead candidate.
FEATURED ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
